Inclusion of Extracapsular Spread in the pTNM Classification System

Juan, Julia de; García, José María Sánchez; López, Montserrat; Orús, César; Esteller, Eduard Carbonell i; Quer, Miquel; León, Xavier

doi:10.1001/jamaoto.2013.2666

Cited by 93 publications

(66 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,15,48–52 Our results reveal a correlation between the elevated markers and adverse histopathological features of the tumor. We assume that by using clinically available serum markers, clinicians can predict unfavorable histopathological parameters before surgical procedures.…”

Section: Discussionmentioning

confidence: 51%

Preoperative SCC Antigen, CRP Serum Levels, and Lymph Node Density in Oral Squamous Cell Carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 51%

Preoperative SCC Antigen, CRP Serum Levels, and Lymph Node Density in Oral Squamous Cell Carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Clinically, this is classified as synchronous nodal metastasis and is an indicator of a poor prognosis. Five-year adjusted survival rates range from approximately 30% to 60% for patients with synchronous nodal metastasis compared with approximately 85% for patients whose cancer has not metastasized (6). Patients with synchronous nodal metastasis are also more likely to develop locoregional or distant metastatic recurrence of HNSCC after completing curative-intent therapy (7).…”

Section: Introductionmentioning

confidence: 99%

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

Hedberg¹,

Goh²,

Chiosea³

et al. 2015

Journal of Clinical Investigation

157

View full text Add to dashboard Cite

BACKGROUND.Recurrence and/or metastasis occurs in more than half of patients with head and neck squamous cell carcinoma (HNSCC), and these events pose the greatest threats to long-term survival. We set out to identify genetic alterations that underlie recurrent/metastatic HNSCC. METHODS.Whole-exome sequencing (WES) was performed on genomic DNA extracted from fresh-frozen whole blood and patient-matched tumor pairs from 13 HNSCC patients with synchronous lymph node metastases and 10 patients with metachronous recurrent tumors. Mutational concordance within and between tumor pairs was used to analyze the spatiotemporal evolution of HNSCC in individual patients and to identify potential therapeutic targets for functional evaluation.RESULTS. Approximately 86% and 60% of single somatic nucleotide variants (SSNVs) identified in synchronous nodal metastases and metachronous recurrent tumors, respectively, were transmitted from the primary index tumor. Genes that were mutated in more than one metastatic or recurrent tumor, but not in the respective primary tumors, include C17orf104, inositol 1,4,5-trisphosphate receptor, type 3 (ITPR3), and discoidin domain receptor tyrosine kinase 2 (DDR2). Select DDR2 mutations have been shown to confer enhanced sensitivity to SRC-family kinase (SFK) inhibitors in other malignancies. Similarly, HNSCC cell lines harboring endogenous and engineered DDR2 mutations were more sensitive to the SFK inhibitor dasatinib than those with WT DDR2. CONCLUSION.In this WES study of patient-matched tumor pairs in HNSCC, we found synchronous lymph node metastases to be genetically more similar to their paired index primary tumors than metachronous recurrent tumors. This study outlines a compendium of somatic mutations in primary, metastatic, and/or recurrent HNSCC cancers, with potential implications for precision medicine approaches. FUNDING.

show abstract

“…Several studies have analyzed prognostic factors related to the nodal recurrence in HNSCC patients. These factors include regional extent of the disease [3,4], location of lymph node metastasis [5], and presence of extracapsular spread [6,7]. For patients treated with surgery on the primary location of the tumor, the resection margin status and the depth of tissue invasion are also considered [2,8].…”

Section: Introductionmentioning

confidence: 99%

Expression of the CXCL12/CXCR4 chemokine axis predicts regional control in head and neck squamous cell carcinoma

León

Diez

García

et al. 2016

Eur Arch Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

Expression of the CXCL12/CXCR4 chemokine axis has been related with the appearance of metastatic recurrence survival, including regional and distant recurrence, in patients with head and neck squamous cell carcinoma (HNSCC). RT-PCR was used to determine mRNA expression levels of CXCL12 and CXCR4 in biopsy tumor samples in 111 patients with HNSCC. Five-year regional recurrence-free survival for patients with low CXCR4 expression (n = 39, 31.5 %) was 97.4 %, for patients with high CXCR4/high CXCL12 expression (n = 22, 19.8 %) it was 94.7 %, and for patients with high CXCR4/low CXCL12 expression (n = 50, 45.0 %) it was 63.3 %. We found significant differences in the regional recurrence-free survival according to CXCR4/CXCL12 expression values (P = 0.001). HNSCC patients with high CXCR4 and low CXCL12 expression values had a significantly higher risk of regional recurrence and could benefit from a more intense treatment of lymph node areas in the neck.

show abstract

Inclusion of Extracapsular Spread in the pTNM Classification System

Abstract: The inclusion of information about ECS in the neck dissection improved the prognostic classification of patients with HNSCC in relation to the pTNM classification.

Cited by 93 publications

References 36 publications

Preoperative SCC Antigen, CRP Serum Levels, and Lymph Node Density in Oral Squamous Cell Carcinoma

Preoperative SCC Antigen, CRP Serum Levels, and Lymph Node Density in Oral Squamous Cell Carcinoma

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

Expression of the CXCL12/CXCR4 chemokine axis predicts regional control in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About